Serum Levels of Soluble Form of Receptor for Advanced Glycation End Products (sRAGE) Are Correlated with AGEs in Both Diabetic and Non-diabetic Subjects

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2008 Jan 12

PMID 18188534

Citations 23

Authors

K Nakamura

S I Yamagishi

T Matsui

H Adachi

M Takeuchi

T Imaizumi

Affiliations

Soon will be listed here.

Citing Articles

Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis.

Chen Q, Liu L, Ke W, Li X, Xiao H, Li Y BMC Endocr Disord. 2024; 24(1):232.

PMID: 39472884 PMC: 11523792. DOI: 10.1186/s12902-024-01759-2.

The AGE-RAGE Axis and the Pathophysiology of Multimorbidity in COPD.

Reynaert N, Vanfleteren L, Perkins T J Clin Med. 2023; 12(10).

PMID: 37240472 PMC: 10219583. DOI: 10.3390/jcm12103366.

Effects of Toxic AGEs (TAGE) on Human Health.

Takeuchi M, Sakasai-Sakai A, Takata T, Takino J, Koriyama Y Cells. 2022; 11(14).

PMID: 35883620 PMC: 9317028. DOI: 10.3390/cells11142178.

Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle.

Takeuchi M Diabetol Metab Syndr. 2020; 12(1):105.

PMID: 33292465 PMC: 7708159. DOI: 10.1186/s13098-020-00614-3.

Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.

Wannamethee S, Welsh P, Papacosta O, Ellins E, Halcox J, Whincup P Atherosclerosis. 2017; 264:36-43.

PMID: 28759844 PMC: 5603971. DOI: 10.1016/j.atherosclerosis.2017.07.008.

References

Yamagishi S, Imaizumi T . Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005; 11(18):2279-99. DOI: 10.2174/1381612054367300. View

Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T . Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med. 2007; 13(3-4):185-9. PMC: 1892766. DOI: 10.2119/2006–00090.Nakamura. View

Humpert P, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth P . Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol. 2007; 6:9. PMC: 1821011. DOI: 10.1186/1475-2840-6-9. View

Pachydaki S, Tari S, Lee S, Ma W, Tseng J, Sosunov A . Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res. 2005; 82(5):807-15. DOI: 10.1016/j.exer.2005.09.022. View

Kass D, Shapiro E, Kawaguchi M, Capriotti A, Scuteri A, deGroof R . Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001; 104(13):1464-70. DOI: 10.1161/hc3801.097806. View

Miura J, Yamamoto Y, Osawa M, Watanabe T, Yonekura H, Uchigata Y . Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol. 2006; 27(1):253-4. DOI: 10.1161/01.ATV.0000251533.18013.67. View

Enomoto M, Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A . Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism. 2006; 55(7):912-7. DOI: 10.1016/j.metabol.2006.02.019. View

Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y . Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res. 2005; 70(3):137-41. DOI: 10.1016/j.mvr.2005.10.002. View

Steiner M, Reinhardt K, Krammer B, Ernst B, Blann A . Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost. 1994; 72(6):979-84. View

10.

Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S . Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005; 25(12):2587-93. DOI: 10.1161/01.ATV.0000190660.32863.cd. View

11.

Park L, Raman K, Lee K, Lu Y, Ferran Jr L, Chow W . Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998; 4(9):1025-31. DOI: 10.1038/2012. View